Phase II trial of cimetidine in metastatic melanoma. A hoosier oncology group trial

R. Mandanas, S. Schultz, D. Scullin, L. H. Einhorn

Research output: Contribution to journalArticle

13 Scopus citations


Fifteen evaluable patients with metastatic malignant melanoma who had received no prior chemotherapy were treated with high-dose cimetidine orally, 600 mg q.i.d. Although three patients had stable disease lasting 2-4 months, there were no objective responses. Median survival was 5.3 months (range 1-18 months). Toxicity was essentially negligible except for severe diarrhea in one patient and worsening liver function abnormalities in another. High-dose cimetidine does not have any significant activity in metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)397-399
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number5
StatePublished - Jan 1 1991


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this